Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects With Benign Masseteric Hypertrophy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 19 Dec 2017 New trial record